- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02827916
Exploration of Neuropathic Pain Induced by Oxaliplatin Electrophysiological Approach (CANALOXA)
Exploration of Neuropathic Pain Induced by Oxaliplatin Electrophysiological Approach: Interest Using the SUDOSCAN® Machine
Oxaliplatin is an anticancer agent commonly used in the treatment of colorectal cancer. However, the development of neuropathic pain under treatment limits its use. These are manifested by acute hyperesthesia / distal cold allodynia and chronic course of hypoesthesia.
It is widely reported that these pains are consecutive to hyperexcitability of some ioniques2 channels (mainly sodium and potassium channels). However, the pathophysiological mechanisms of neurotoxicity are multifactorial and still imperfectly described.
Since May 2014, the hospital group Paris Saint Joseph led the pilot study LIPIDOXA whose challenge is to quantify / measure NAION and explained by a biochemical approach, specifically Lipidomics. The CANALOXA study is the logical continuation of LIPIDOXA study insofar design methodology relies heavily on techniques developed for LIPIDOXA study and that the expected results will be complementary to those of LIPIDOXA.
Study Overview
Status
Conditions
Detailed Description
Main objective:
it is, in cancer patients chronically treated with oxaliplatin (over 5 courses) and exhibiting signs of neuropathy, to correlate the quantitative changes in the thermal sensitivity to hot and cold (Thermotest, Quantitative Sensory Testing QST ) with any changes in the ion conductance chlorine measured by electrophysiological technique (SUDOSCAN).
Secondary objectives:
- Correlating the results obtained with both types of techniques and with the descriptive parameters of the population included.
- Understand the importance of regulating the activity of the chloride channel in the development of neuropathy induced by oxaliplatin.
Methodology :
Prospective study, single center, intervention in routine care. Time study: February 2015 - October 2016
- Evaluation of neuropathy by electrophysiological methods (SUDOSCAN) The SUDOSCAN is a new technology fast and non-invasive to quantify the degree of neuropathy objectively through evaluation of chloride conductance at the skin of the palms and the soles of pieds4,5.
Evaluation of neuropathy by devices for quantitative measurement of neuropathic pain
The pain symptoms was evaluated through various semi-objective neuropathy quantification tools (Quantitative Sensory Testing devices) 6:
- The Thermotest (Somedic®): medical device that measures the thermal sensitivity thresholds to cold and hot: cold sensitivity threshold, threshold of sensitivity to hot, cold pain threshold, pain threshold warm. These stimuli are transmitted by the fiber Adelta and C. Since dysesthesia to thermal stimuli (allodynia in acute and chronical hypoesthesia) are typical of oxaliplatin, Thermotest is fundamental.
- Questionnaire NPSI (Neuropathic Pain Symptom Inventory) widely used in the field and validated.
- Statistical Analysis: Professor Gilles Chatellier, statistician (Clinical Research Unit, Hôpital Européen Georges Pompidou) will bring its expertise in statistical analysis.
NB: For each subject will be awarded an identifier (simple counter: increment as and measurement of inclusions) and the data will be entered on a computer file which will be sent to the statistician in charge of the analysis. There will be no exchange of personal data for this study is single center on the site GHPSJ.
Development of the study:
- Inclusion of patients treated with oxaliplatin from 6th cycle (FOLFOX protocols FOLFIRINOX, EOX, GEMOX, EOF, XELOX).
- Expected duration of patient recruitment: 9 months
- Number of patients to recruit and duration of participation for each patient: Based on 75 patients seen in 9 months in GHSPJ the oncology department for cancer of the digestive tract, and knowing that the prevalence of neuropathic pain in oxaliplatin is 50-70% (Attal 2009), the investigators plan to include at least 36 patients in this period of 9 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ile-de-France
-
Paris, Ile-de-France, France, 75014
- Groupe hospitalier Paris saint Joseph
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient newly treated with oxaliplatin
- Patient suffering from any type of cancer treated with oxaliplatin
- Man or Woman over 18
Exclusion Criteria:
- Patient with brain or leptomeningeal metastases
- Patient previously treated with cisplatin
- Patient addicted to alcohol
- Diabetic patient with peripheral neurological disorders
- Patient receiving calcium or magnesium salts intravenously
- Patient suffering from peripheral neuropathy
- Patient suffering from psychiatric disorders
- Patient treated with at least one of the following drug: venlafaxine, carbamazepine, gabapentin, pregabalin, clomipramine, amitriptyline, imipramine, duloxetine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: All patients
Measure of painful neuropathy for al patients with thermotest and sudoscan Devices and Neuropathic Pain Symptom Inventory.
|
Measure of painful neuropathy with thermotest
Measure of painful neuropathy with sudoscan Devices
Measure of painful neuropathy with Neuropathic Pain Symptom Inventory.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of neuropathy by electrophysiological methods using SUDOSCAN
Time Frame: Day 1
|
The SUDOSCAN is a new technology fast and non-invasive to quantify the degree of neuropathy objectively through evaluation of chloride conductance of the skin on the palm of the hand and soles of the feet2).
This can evaluate the neuropathy for quantitative measurement of neuropathic pain
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of neuropathy by devices for quantitative measurement of neuropathic pain
Time Frame: Day 1
|
The pain symptoms are evaluated through various semi- objective neuropathy quantification tools (Quantitative Sensory Testing devices)6 : - Le Thermotest (Somedic®) : medical device that measures the thermal sensitivity thresholds to cold and hot: cold sensitivity threshold, threshold of sensitivity to hot, cold pain threshold, pain threshold warm. These stimuli are transmitted by the fiber Adelta and C. Since dysesthesia to thermal stimuli (allodynia in acute and hypoesthesia in chroniqe) are typical of oxaliplatin, Thermotest is fundamental. |
Day 1
|
NPSI ange of Characterization of pain neuropathy
Time Frame: Day 1
|
Questionnaire NPSI (Neuropathic Pain Symptom Inventory) widely used in the field and validated.
|
Day 1
|
Collaborators and Investigators
Investigators
- Principal Investigator: COUDORE Francois, MD, Groupe hospitalier Paris saint Joseph
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CANALOXA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheric Neuropathy
-
Zekai Tahir Burak Women's Health Research and Education...UnknownCerebral Oxygenation | Peripheric Oxygenation | Polycythaemic InfantsTurkey
-
Arash Asher, MDVoxxLifeRecruitingNeuropathy | Chemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
Henry Ford Health SystemOctapharma USA, Inc.RecruitingSmall Fiber Neuropathy | Autoimmune Small Fiber Neuropathy | Inflammatory Polyneuropathy | Immune-Mediated NeuropathyUnited States
-
Nihon Pharmaceutical Co., LtdCompletedMultifocal Motor NeuropathyJapan
-
University of AarhusCompletedMultifocal Motor NeuropathyDenmark
-
Beth Israel Deaconess Medical CenterPhoenix Neurological Associates, LTDCompletedSmall Fiber Neuropathy | Idiopathic Peripheral NeuropathyUnited States
-
Tanta UniversityCompletedDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Painful Diabetic Neuropathy | Autonomic Neuropathy | Diabetic Polyneuropathy | Small Fiber NeuropathyEgypt
-
Yung-Tsan WuCompleted
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Sorlandet Hospital HFOslo University Hospital; University Hospital of North Norway; University Hospital...Not yet recruitingSmall Fiber Neuropathy | Sensory Neuropathy
Clinical Trials on Assessment of neuropathic pain with theThermotest device
-
University of DundeeWellcome Trust; Diabetes UKCompletedDiabetic Neuropathic PainUnited Kingdom
-
University Hospital Center of MartiniqueInstitut National de la Santé Et de la Recherche Médicale, France; Clinique...RecruitingFever | Dengue | Chikungunya | Zika VirusFrance, French Guiana, Guadeloupe, Martinique, Réunion
-
Centre hospitalier de l'Université de Montréal...Completed
-
Groupe Hospitalier Paris Saint JosephCompletedChronic Postoperative PainFrance
-
Bursa Yüksek İhtisas Education and Research HospitalCompletedCentral Sensitisation | Behcet's DiseaseTurkey
-
Lund UniversityCompleted
-
NHS Greater Glasgow and ClydeBuckinghamshire Healthcare NHS TrustNot yet recruitingSpinal Cord Injuries | Central Neuropathic PainUnited Kingdom
-
Gaziler Physical Medicine and Rehabilitation Education...CompletedNeuropathic PainTurkey
-
University Hospital, MontpellierUnknown
-
Swallis MedicalRecruiting